Previous 10 | Next 10 |
Additional data to be presented from the ongoing phase 1/2 study of BION-1301 in patients with IgA nephropathy, including biomarker and proteinuria reductions Several presentations on the atrasentan clinical program, including translational research demonstrating E...
A list of 62 recent IPOs debuted on The Russell 2000 small-cap index after index provider FTSE Russell implemented its Q3 reconstitution. Following up on our previous article on recently-IPOd biotech stocks joining the index, in this article, we discuss another four biotechs ma...
On August 18, Chinook Therapeutics (NASDAQ:KDNY) Director, Srinivas Akkaraju bought 208,500 shares of the company at price of $11.58. This brings his total share holding to ~3.38M shares. The stock increased ~6.3% on Monday, August 23. Source For further details see: Chinook Therapeutic...
SEATTLE, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the s...
SEATTLE, July 12, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a ...
Chinook is a unique business with both a late-stage pipeline and platform in kidney disease. The company in-licensed a compelling drug candidate from AbbVie that is undergoing phase 3 trials for a rare kidney disease and a phase 2 trial for broader indications. Chinook is also bui...
Gainers: Geron (GERN) +22%, AnPac Bio-Medical Science (ANPC) +20%, CureVac (CVAC) +13%, Crinetics Pharmaceuticals (CRNX) +7%, Seres Therapeutics (MCRB) +7%.Losers: Orphazyme (ORPH) -41%, Athira Pharma (ATHA) -41%, Chinook Therap...
Chinook Therapeutics (KDNY) announces the promotions of Tom Frohlich and Andrew King to the roles of chief operating officer ((COO)) and chief scientific officer ((CSO)).Frohlich is currently serving as the company's chief business officer, while King is the head of renal ...
SEATTLE, June 09, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Tom Frohlich, chief business officer,...
Chinook Therapeutics ([[KDNY]] +10.2%) presents data from its ongoing phase 1/2 study of BION-1301 in patients with IgA Nephropathy (IgAN). BION-1301 has been well-tolerated, with no treatment-related or severe adverse events, or treatment discontinuations due to adverse events.Pharmacok...
News, Short Squeeze, Breakout and More Instantly...
Chinook Therapeutics Inc Com Company Name:
KDNY Stock Symbol:
NASDAQ Market:
Chinook Therapeutics Inc Com Website:
Chinook Therapeutics, Inc. (NASDAQ: KDNY) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 2.86% on the day to $40.3. Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, dev...
SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enr...
NEW YORK, NY / ACCESSWIRE / July 27, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Sculptor Capital Management Inc. (NYS...